0
     

Report Added
Report already added
Isotretinoin Drugs Market - Forecast till 2027

Isotretinoin Drugs Market - Forecast till 2027

Isotretinoin Drugs Market - Forecast till 2027

Market Forecast
The global isotretinoin drugs market is anticipated to register a significant CAGR of 4.68% during the forecast period to surpass a market value of USD 1,652.40 million by the end of 2027.
The global isotretinoin drug market is expected to register a notable market expansion during the review period owing to the growing incidences of acne among people and neuroblastoma. Additionally, the emergence of micronized formation for serious recalcitrant nodular acne cure creates lucrative scope for the global market. Besides, the concerns relating to drug side-effects are anticipated to hamper the global market growth.

The admission of isotretinoin drug presents wellbeing gambles among pregnant ladies. The medication can cause a few birth deformities, for example, the congenital fissure and inherent heart deserts among others. Likewise, unnatural birth cycle and stillbirth are a portion of the significant incidental effects set off by the utilization of the isotretinoin drug. Different confusions impeding the isotretinoin drugs market incorporate dry skin, seriously dried out lips, nosebleeds, dry and disturbed eyes, and dry mouth. The medicine was additionally answered to cause transitory secondary effects like deteriorating of skin inflammation, night visual impairment, diminishing hair, and muscle or joint agony. Also, rashes, stomach issues, and unfortunate cholesterol levels are the interesting conceivable aftereffects that singular encounters during the admission of isotretinoin drugs.

Market Segmentation
The Global Isotretinoin Drugs Market is classified based on Form, indication, distribution channel, and others. By form segment, the global market has been bifurcated into Injection and Capsule.
Based on Indication the market is classified into Severe acne, Squamous cell carcinoma, cutaneous T-cell lymphoma, Neuroblastoma, Harlequin ichthyosis, Xeroderma pigmentosum, and Fibrodysplasia ossificans progressive.
The Distribution Channel divides the market into three main types namely Hospital pharmacies, Retail Pharmacies, and Online pharmacies.

Region-Specific Analysis
North America represented a market size of USD 468.76 million of every 2020 and is relied upon to show a 5.06% CAGR during the review time frame. The isotretinoin drugs market is filling in the area because of created medical care framework, good unofficial laws, the rising pervasiveness of different skin issues, hereditary issues, and malignant growth, as well as expanded R&D venture.
The Asia-Pacific isotretinoin drugs market is relied upon to develop at a CAGR of 6.18% somewhere in the range of 2021 and 2027. The presence of a few market players in the region, for example, Sun Pharma organization (India) and Dr. Reddy's Laboratories Ltd (India), is driving the territorial market development. Moreover, because of the expansion in financing from financial backers, the utilization of isotretinoin is ceaselessly ascending among the clients in more burdened regions, with Asia seeing a relatively higher expansion being used.

Major Players
The key players in the global isotretinoin drugs market are Teva Pharmaceuticals Industries, Akorn (US), Catalent Pharma Solutions (US), Chongqing Huapont (China), Inc. (Israel), Dr. Reddy’s Laboratories (India), Douglas Pharmaceuticals Ltd (New Zealand), F. Hoffmann La Roche (Europe)., Mylan (US), Cipher Pharmaceuticals (US), GlaxoSmithKline (UK), and Sun Pharmaceuticals (India).

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF ACNE AMONG TEENS AND YOUNG ADULTS
4.2.2 INCREASING INCIDENCE OF NEUROBLASTOMA
4.3 RESTRAINT
4.3.1 CONCERNS PERTAINING TO DRUG SIDE EFFECTS
4.4 OPPORTUNITY
4.4.1 INTRODUCTION OF NEW MICRONIZED FORMATION FOR SEVERE RECALCITRANT NODULAR ACNE TREATMENT
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON ISOTRETINOIN DRUGS MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON THE ISOTRETINOIN DRUGS MARKET
5.3.3 IMPACT ON GDP AND HEALTHCARE EXPENDITURE
5.4 OFF LABEL USAGE OF ISOTRETINOIN CAPSULES
5.5 BY INDICAITION ANALYSIS ON PRESCRIBED PERSONNEL AND DOSAGE
6 GLOBAL ISOTRETINOIN DRUGS MARKET, BY FORM
6.1 OVERVIEW
6.2 CAPSULE
6.3 INJECTION
7 GLOBAL ISOTRETINOIN DRUGS MARKET, BY INDICATION
7.1 OVERVIEW
7.2 SEVERE ACNE
7.3 SQUAMOUS CELL CARCINOMA
7.4 CUTANEOUS T-CELL LYMPHOMA
7.5 NEUROBLASTOMA
7.6 HARLEQUIN ICHTHYOSIS
7.7 XERODERMA PIGMENTOSUM
7.8 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
7.9 OTHERS
8 GLOBAL ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL
8.1 OVERVIEW
8.2 HOSPITAL PHARMACIES
8.3 RETAIL PHARMACIES
8.4 ONLINE PHARMACIES
9 GLOBAL ISOTRETINOIN DRUGS MARKET, BY REGION
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 UK
9.3.4 ITALY
9.3.5 RUSSIA
9.3.6 SPAIN
9.3.7 UKRAINE
9.3.8 REST OF EUROPE
9.4 ASIA-PACIFIC
9.4.1 CHINA
9.4.2 INDIA
9.4.3 JAPAN
9.4.4 SOUTH KOREA
9.4.5 AUSTRALIA
9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
9.5.1 MIDDLE EAST
9.5.2 AFRICA
9.5.3 LATIN AMERICA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPETITIVE BENCHMARKING
10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL ISOTRETINOIN DRUGS MARKET
10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL ISOTRETINOIN DRUGS MARKET
10.5 KEY DEVELOPMENT ANALYSIS
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 PRODUCT LAUNCHES/PRODUCT APPROVALS
10.6.2 EXPANSIONS
10.7 FINANCIAL MATRIX
10.7.1 SALES (USD MILLION), 2020
10.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2020
11 COMPANY PROFILES
11.1 DOUGLAS PHARMACEUTICALS LIMITED
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS/SERVICES OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS/SERVICES OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 AKORN OPERATING COMPANY LLC
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS/SERVICES OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIES
11.4 DR. REDDY’S LABORATORIES LTD
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS/SERVICES OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.4.6 KEY STRATEGIES
11.5 F. HOFFMAN LA ROCHE LTD
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS/SERVICES OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 SWOT ANALYSIS
11.5.6 KEY STRATEGIES
11.6 MYLAN NV
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS/SERVICES OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 KEY STRATEGIES
11.7 SUN PHARMACEUTICALS
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.7.6 KEY STRATEGIES
11.8 CIPHER PHARMACEUTICALS INC.
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL ANALYSIS
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIES
11.9 GLAXOSMITHKLINE PLC
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL ANALYSIS
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 SWOT ANALYSIS
11.9.6 KEY STRATEGIES
11.10 CHONGQING HUAPONT
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL ANALYSIS
11.10.3 PRODUCTS OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIES
11.11 CATALENT PHARMA SOLUTIONS
11.11.1 COMPANY OVERVIEW
11.11.2 FINANCIAL ANALYSIS
11.11.3 PRODUCTS OFFERED
11.11.4 KEY DEVELOPMENTS
11.11.5 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS



LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
TABLE 3 GLOBAL: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018–2027 (USD MILLION)
TABLE 4 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR CAPSULE, BY REGION, 2018–2027 (USD MILLION)
TABLE 5 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR INJECTION, BY REGION, 2018–2027 (USD MILLION)
TABLE 6 GLOBAL: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018–2027 (USD MILLION)
TABLE 7 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR SEVERE ACNE, BY REGION, 2018–2027 (USD MILLION)
TABLE 8 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR SQUAMOUS CELL CARCINOMA, BY REGION, 2018–2027 (USD MILLION)
TABLE 9 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR CUTANEOUS T-CELL LYMPHOMA, BY REGION, 2018–2027 (USD MILLION)
TABLE 10 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR NEUROBLASTOMA, BY REGION, 2018–2027 (USD MILLION)
TABLE 11 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR HARLEQUIN ICHTHYOSIS, BY REGION, 2018–2027 (USD MILLION)
TABLE 12 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR XERODERMA PIGMENTOSUM, BY REGION, 2018–2027 (USD MILLION)
TABLE 13 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA, BY REGION, 2018–2027 (USD MILLION)
TABLE 14 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR OTHERS, BY REGION, 2018–2027 (USD MILLION)
TABLE 15 GLOBAL: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018–2027 (USD MILLION)
TABLE 16 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2018–2027 (USD MILLION)
TABLE 17 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR RETAIL PHARMACIES, BY REGION, 2018–2027 (USD MILLION)
TABLE 18 GLOBAL: ISOTRETINOIN DRUGS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2018–2027 (USD MILLION)
TABLE 19 GLOBAL: ISOTRETINOIN DRUGS MARKET, BY REGION, 2018–2027 (USD MILLION)
TABLE 20 NORTH AMERICA: ISOTRETINOIN DRUGS MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 21 NORTH AMERICA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 22 NORTH AMERICA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 23 NORTH AMERICA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 24 US: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 25 US: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 26 US: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 27 CANADA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 28 CANADA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 29 CANADA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 30 EUROPE: ISOTRETINOIN DRUGS MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 31 EUROPE: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 32 EUROPE: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 33 EUROPE: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 34 GERMANY: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 35 GERMANY: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 36 GERMANY: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 37 FRANCE: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 38 FRANCE: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 39 FRANCE: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 40 UK: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 41 UK: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 42 UK: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 43 ITALY: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 44 ITALY: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 45 ITALY: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 46 RUSSIA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 47 RUSSIA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 48 RUSSIA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 49 SPAIN: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 50 SPAIN: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 51 SPAIN: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 52 UKRAINE: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 53 UKRAINE: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 54 UKRAINE: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 55 REST OF EUROPE: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 56 REST OF EUROPE: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 57 REST OF EUROPE: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 58 ASIA-PACIFIC: ISOTRETINOIN DRUGS MARKET, BY COUNTRY, 2018-2027 (USD MILLION)
TABLE 59 ASIA-PACIFIC: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 60 ASIA-PACIFIC: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 61 ASIA-PACIFIC: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 62 CHINA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 63 CHINA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 64 CHINA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 65 INDIA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 66 INDIA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 67 INDIA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 68 JAPAN: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 69 JAPAN: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 70 JAPAN: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 71 SOUTH KOREA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 72 SOUTH KOREA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 73 SOUTH KOREA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 74 AUSTRALIA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 75 AUSTRALIA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 76 AUSTRALIA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 77 REST OF ASIA-PACIFIC: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 78 REST OF ASIA-PACIFIC: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 79 REST OF ASIA-PACIFIC: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 80 REST OF THE WORLD: ISOTRETINOIN DRUGS MARKET, BY REGION, 2018–2027 (USD MILLION)
TABLE 81 REST OF THE WORLD: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 82 REST OF THE WORLD: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 83 REST OF THE WORLD: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 84 MIDDLE EAST: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 85 MIDDLE EAST: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 86 MIDDLE EAST: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 87 AFRICA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 88 AFRICA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 89 AFRICA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 90 LATIN AMERICA: ISOTRETINOIN DRUGS MARKET, BY FORM, 2018-2027 (USD MILLION)
TABLE 91 LATIN AMERICA: ISOTRETINOIN DRUGS MARKET, BY INDICATION, 2018-2027 (USD MILLION)
TABLE 92 LATIN AMERICA: ISOTRETINOIN DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)
TABLE 93 MAJOR PLAYERS IN THE GLOBAL ISOTRETINOIN DRUGS MARKET
TABLE 94 MOST ACTIVE PLAYER IN THE GLOBAL ISOTRETINOIN DRUGS MARKET
TABLE 95 PRODUCT LAUNCHES/PRODUCT APPROVALS
TABLE 96 EXPANSIONS
TABLE 97 DOUGLAS PHARMACEUTICALS LIMITED: PRODUCTS/SERVICES OFFERED
TABLE 98 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS/SERVICES OFFERED
TABLE 99 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS
TABLE 100 AKORN OPERATING COMPANY LLC: PRODUCTS/SERVICES OFFERED
TABLE 101 DR. REDDY’S LABORATORIES LTD: PRODUCTS/SERVICES OFFERED
TABLE 102 DR. REDDY’S LABORATORIES LTD: KEY DEVELOPMENTS
TABLE 103 F. HOFFMAN LA ROCHE LTD: PRODUCTS/SERVICES OFFERED
TABLE 104 MYLAN NV: PRODUCTS/SERVICES OFFERED
TABLE 105 SUN PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 106 SUN PHARMACEUTICALS: KEY DEVELOPMENTS
TABLE 107 CIPHER PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 108 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED
TABLE 109 CHONGQING HUAPONT: PRODUCTS OFFERED
TABLE 110 CATALENT PHARMA SOLUTIONS: PRODUCTS OFFERED
TABLE 111 CATALENT PHARMA SOLUTIONS: KEY DEVELOPMENTS

Report Title: Isotretinoin Drugs Market - Forecast till 2027


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

China Bispecific Antibody Market Opportunity & Clinical Trials Insight 2028

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Vietnam Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Venezuela Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Uruguay Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 United Arab Emirates Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline

2022 Ukraine Clinical Chemistry and Immunodiagnostic Analyzers and Reagents for 100 Abused Drug, Cancer, Chemistry, Endocrine, Immunoprotein, TDM and Other Tests -- High-Growth Opportunities for Suppliers, Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts through 2026, Latest Technologies and Instrumentation Pipeline